Market research
PHGN.F Pharming Group N.V
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 697M
- P/E ratio
- 98.54
- Analyst target
- 1.49
- Dividend yield
- Not available
- Beta
- 0.06
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0010391025
- Market cap
- 697M
- P/E ratio
- 98.54
- Analyst target
- 1.49
- Dividend yield
- Not available
- Beta
- 0.06
About
About Pharming Group N.V
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PHGN.F discussion.
5 years, 4 months ago
Pharming Group N.V is currently in a long term downtrend where the price is trading 10.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Pharming Group N.V's total revenue rose by 1.0% to $46M since the same quarter in the previous year.
Its net income has dropped by 38.6% to $7M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.4% to $16M since the same quarter in the previous year.
Based on the above factors, Pharming Group N.V gets an overall score of 2/5.